A Phase 2 Study of LY573636-Sodium [tasisulam] Administered as Second-Line or Third-Line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2010
At a glance
- Drugs Tasisulam (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 21 Nov 2009 Last checked against M.D. Anderson Cancer Center record.